作者
Frederik Persson, Peter Rossing, Priya Vart, Glenn M Chertow, Fan Fan Hou, Niels Jongs, John JV McMurray, Ricardo Correa-Rotter, Harpreet S Bajaj, Bergur V Stefansson, Robert D Toto, Anna Maria Langkilde, David C Wheeler, Hiddo JL Heerspink
发表日期
2021/8/1
期刊
Diabetes care
卷号
44
期号
8
页码范围
1894-1897
出版商
American Diabetes Association
简介
OBJECTIVE
The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular outcomes with dapagliflozin versus placebo in participants with chronic kidney disease (CKD) with and without diabetes. We compared outcomes according to baseline glycemic status.
RESEARCH DESIGN AND METHODS
We enrolled participants with CKD, estimated glomerular filtration rate (eGFR) 25–75 mL/min/1.73 m2, and urinary albumin-to-creatinine ratio 200–5,000 mg/g. The primary composite end point was sustained eGFR decline ≥50%, end-stage kidney disease, or kidney or cardiovascular death.
RESULTS
Of 4,304 participants, 738 had normoglycemia, 660 had prediabetes, and 2,906 had type 2 diabetes. The effect of dapagliflozin on the primary outcome was consistent …
学术搜索中的文章
F Persson, P Rossing, P Vart, GM Chertow, FF Hou… - Diabetes Care, 2021